Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TTR | P02766 | 1/20 | 0.46 |
| ▸ | MGLL | Q99685 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | CA12 | O43570 | 6/20 | 0.38 |
| ▸ | CA7 | P43166 | 1/20 | 0.38 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | CA1 | P00915 | 5/20 | 0.36 |
| ▸ | CA9 | Q16790 | 5/20 | 0.36 |
| ▸ | CA2 | P00918 | 4/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | PDK1 | Q15118 | 2/20 | 0.33 |
| ▸ | PDK2 | Q15119 | 2/20 | 0.33 |
| ▸ | PDK3 | Q15120 | 2/20 | 0.33 |
| ▸ | FAAH | O00519 | 1/20 | 0.33 |
| ▸ | PHGDH | O43175 | 1/20 | 0.33 |
| ▸ | ALDH2 | P05091 | 1/20 | 0.33 |
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25928 | 0.96 | TTR (0.50) | TTRMGLLSMN1; SMN2CA12CA7 | |
| SCHEMBL31229527 | 0.96 | TTR (0.50) | TTRMGLLSMN1; SMN2CA12CA7 | |
| SCHEMBL27619 | 0.96 | TTR (0.50) | TTRMGLLSMN1; SMN2CA12CA7 | |
| SCHEMBL11552627 | 0.96 | TTR (0.50) | TTRMGLLSMN1; SMN2CA12CA7 | |
| SCHEMBL11554965 | 0.96 | TTR (0.50) | TTRMGLLSMN1; SMN2CA12CA7 | |
| SCHEMBL11583577 | 0.96 | TTR (0.50) | TTRMGLLSMN1; SMN2CA12CA7 | |
| SCHEMBL27017 | 0.96 | TTR (0.50) | TTRMGLLSMN1; SMN2CA12CA7 | |
| Hydrochloric Acid SCHEMBL11584373 | 0.92 | TTR (0.46) | TTRMGLLSMN1; SMN2CA12CA7 | |
| Hydrochloric Acid SCHEMBL15639418 | 0.92 | TTR (0.46) | TTRMGLLSMN1; SMN2CA12CA7 | |
| SCHEMBL10599432 | 0.92 | MGLL (0.47) | TTRMGLLSMN1; SMN2CA12CA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12006302-B2 | Tau PET imaging ligands | JANSSEN PHARMACEUTICA NV (BE) | 2024-06-11 | — | — | US | disclosed |
| US-20220024896-A1 | TAU PET IMAGING LIGANDS | JANSSEN PHARMACEUTICA NV (BE) | 2022-01-27 | — | — | US | disclosed |
| US-11168068-B2 | Tau PET imaging ligands | JANSSEN PHARMACEUTICA NV (BE) | 2021-11-09 | — | — | US | disclosed |
| US-20210283277-A1 | TAU PET IMAGING LIGANDS | JANSSEN PHARMACEUTICA NV (BE) | 2021-09-16 | — | — | US | disclosed |
| EP-3484528-B1 | TAU PET IMAGING LIGANDS | JANSSEN PHARMACEUTICA NV (BE) | 2020-11-25 | — | — | EP | disclosed |
| US-20190284165-A1 | TAU PET IMAGING LIGANDS | JANSSEN PHARMACEUTICA NV (BE) | 2019-09-19 | — | — | US | disclosed |
| EP-3484528-A1 | TAU PET IMAGING LIGANDS | Janssen Pharmaceutica, N.V. (BE) | 2019-05-22 | — | — | EP | disclosed |
| US-20190038784-A1 | TAU PET IMAGING LIGANDS | JANSSEN PHARMACEUTICA NV (BE) | 2019-02-07 | — | — | US | disclosed |
| EP-3411083-A1 | TAU PET IMAGING LIGANDS | Janssen Pharmaceutica NV (BE) | 2018-12-12 | — | — | EP | disclosed |
| WO-2018015307-A1 | TAU PET IMAGING LIGANDS | JANSSEN PHARMACEUTICA NV (BE) | 2018-01-25 | — | — | WO | disclosed |
| WO-2017134098-A1 | TAU PET IMAGING LIGANDS | JANSSEN PHARMACEUTICA NV (BE) | 2017-08-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11168068-B2 | Tau PET imaging ligands | MAPT, PSEN1, APP | TTR 24/4885MGLL 2960/4885SMN1; SMN2 837/4885 |
| US-20190038784-A1 | TAU PET IMAGING LIGANDS | MAPT, PSEN1, APP | TTR 24/4885MGLL 2960/4885SMN1; SMN2 837/4885 |
| US-20220024896-A1 | TAU PET IMAGING LIGANDS | MAPT, PSEN1, APP | TTR 24/4885MGLL 2960/4885SMN1; SMN2 837/4885 |
| US-20190284165-A1 | TAU PET IMAGING LIGANDS | MAPT, PSEN1, APP | TTR 24/4885MGLL 2960/4885SMN1; SMN2 837/4885 |
| US-20210283277-A1 | TAU PET IMAGING LIGANDS | MAPT, PSEN1, APP | TTR 24/4885MGLL 2960/4885SMN1; SMN2 837/4885 |
| US-12006302-B2 | Tau PET imaging ligands | MAPT, PSEN1, APP | TTR 24/4885MGLL 2960/4885SMN1; SMN2 837/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.